Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

Status:
Active, not recruiting

Trial end date:
2023-10-05

Target enrollment:

Participant gender:

This study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.

Phase 3

PTC Therapeutics